| Document |
Document Title |
|
WO/2022/254394A1 |
The present disclosure relates generally to a method of stopping bleeding comprising applying a peptide-based hemostatic material to a bleeding wound, wherein the peptide-based hemostatic material comprises at least one self-assembling u...
|
|
WO/2022/252619A1 |
A fermentation and enzymolysis preparation method for small peptides from a leaf-shaped fish and the use thereof. The preparation process comprises: crushing, degreasing and hydrolyzing a leaf-shaped fish to obtain a hydrolysate; carryin...
|
|
WO/2022/254429A1 |
The present invention relates to the treatment or prevention of respiratory distress using a pharmaceutical composition containing a peptide denoted ZEP3, ZEP4 or a salt thereof.
|
|
WO/2022/246241A1 |
Disclosed herein are cosmetic compositions comprising a Vitamin C compound, a peptide, an antioxidant, and a hydrating agent. Also disclosed is a method visibly improving skin by brightening skin, evening skin tone, tightening skin, plum...
|
|
WO/2022/245070A1 |
The present invention relates to a novel peptide and a cosmetic composition comprising same, and relates to a cosmetic composition comprising a novel peptide derived from Chlorella protothecoides to have an excellent skin-brightening or ...
|
|
WO/2022/238174A1 |
The present invention relates to purification of a tripeptide of formula (I). By using said method, the tripeptide of formula (I) is obtained in a very pure form and due to this effect the purified tripeptide can be used in a variety of ...
|
|
WO/2022/238530A1 |
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
|
|
WO/2022/238565A2 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...
|
|
WO/2022/238173A1 |
The present invention relates to purification of a tripeptide of formula (I). By using said method, the tripeptide of formula (I) is obtained in a very pure form and due to this effect the purified tripeptide can be used in a variety of ...
|
|
WO/2022/234867A1 |
The present invention provides a compound represented by formula [I] having an MMP 7-inhibiting action or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/234864A1 |
It has been found that a cyclic peptide compound can be efficiently produced by linking an N-terminal amino acid residue of a peptide compound to a C-terminal amino acid residue of the peptide compound in a solvent including one or more ...
|
|
WO/2022/234018A1 |
The present invention relates to a method for modeling a cyclic 3D epitope from a surface of a target antigen comprising the steps of: a) identifying, in a 3D model representation of the target antigen, one or more conserved region(s) su...
|
|
WO/2022/234853A1 |
The present inventors found a cyclic compound and an oligopeptide compound that selectively inhibit KRAS. The present inventors further found an oligopeptide compound and a non-natural amino acid that are useful for producing the cyclic ...
|
|
WO/2022/235605A1 |
The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof Formula (I) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions...
|
|
WO/2022/229965A1 |
The present disclosure provides compositions and methods for modulating various mammary' disorders and conditions. The disclosure further provides a therapeutic combination of a composition of at least one casein protein or casein-derive...
|
|
WO/2022/228495A1 |
The present application relates to a preparation method for an antibody-drug conjugate and an application, and in particular, to a compound, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceuti...
|
|
WO/2022/228422A1 |
Provided are a bispecific antibody-drug conjugate comprising a bispecific antibody, a toxin and a linker, a pharmaceutical composition comprising the bispecific antibody-drug conjugate, and the use of the bispecific antibody-drug conjuga...
|
|
WO/2022/229951A1 |
The technology subject of the present application concerns antimicrobial and/or antifouling materials and films made therefrom.
|
|
WO/2022/228494A1 |
The present application relates to a preparation method for and an application of an antibody conjugated drug, in particular to a compound, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutic...
|
|
WO/2022/228493A1 |
A preparation method and an application of an antibody drug conjugate. Specifically relating to a compound, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt,...
|
|
WO/2022/225987A1 |
Provided herein are co-assembling peptides which may form particles (e.g., nanoparticles or granules) under stimulating conditions. Also provided herein are protein carrying particles (e.g., nanoparticles or granules). Further provided h...
|
|
WO/2022/226046A1 |
The present disclosure provides peptide nucleic acids (PNAs) including cyclic structural moieties such as tetrahydrofuran, pyrrolidinium, pyrrolidine, or N-methyl pyrrolidine, which have surprisingly improved the water solubility and bin...
|
|
WO/2022/223805A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...
|
|
WO/2022/221959A1 |
Disclosed herein are cyclopolyphosphazenes of formula (I): methods for the preparation thereof and uses thereof in adjuvant compositions.
|
|
WO/2022/222916A1 |
Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from...
|
|
WO/2022/218250A1 |
Use of a compound represented by formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic, or a composition thereof in preparation of a drug for treating pruritus. Also provided is a method ...
|
|
WO/2022/218415A1 |
A crystal form of an exatecan analog and a preparation method therefor, in particular, a crystal form of a compound as represented by formula (I) and a preparation method therefor. The present crystal form has good physical and chemical ...
|
|
WO/2022/218409A1 |
Disclosed in the present invention is a heptamethylcarbocyanine dye - crosslinked tetracyclic amine chelating agent conjugate, which comprises a cross-linking agent group L and a heptamethylcarbocyanine dye (HMCD) group that is coupled w...
|
|
WO/2022/220232A1 |
[Problem] To provide a fluorescent probe capable of detecting pancreatic cancer specifically. [Solution] A fluorescent probe for use in the detection of pancreatic cancer, which comprises a compound represented by general formula (I) or ...
|
|
WO/2022/215758A1 |
Provided are a lipid and a composition which are capable of effectively delivering an introduced compound such as a nucleic acid to, for instance, a target cell or tissue in vivo. The lipid according to the present invention is a lipid...
|
|
WO/2022/206587A1 |
A polypeptide compound having a structure shown in formula I, or a stereoisomer, mixture or pharmaceutically acceptable salt thereof. Experimental results show that the polypeptide compound can effectively exhibit high agonistic activity...
|
|
WO/2022/212367A1 |
Disclosed herein are anionic boron compounds. The anionic boron compounds include anionic boronic heterocycles, optionally ligated with carbenes. The anionic boron compounds are useful synthetic intermediates for boron heterocycles, as w...
|
|
WO/2022/204945A1 |
It relates to a composition for caring for keratin materials comprising in water: a) from 0.2 wt.% to 10 wt.% of a peptide of formula (I), relative to the total weight of the composition: R1-L-Tyr-L-Arg-R2 (I) wherein: R1 is an R3-C=O gr...
|
|
WO/2022/211624A1 |
The invention relates to self-assembling peptide (nano)fibers, hydrogels, and methods, uses and intermediate products and kits relating thereto. Provided is a method for providing peptide-based functionally modified (nano)fibers, compris...
|
|
WO/2022/208262A1 |
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...
|
|
WO/2022/202880A1 |
The purpose of the present invention is to provide: a lipid bilayer disc which can be produced easily, makes it possible to disperse a hydrophobic compound or the like in water satisfactorily, and has excellent transparency and stability...
|
|
WO/2022/199237A1 |
Provided are modified amino acids and an application thereof in ADC. The modified amino acids are phosphorylcholine group-modified amino acids represented by R1-L1-N(R2)-R3, wherein R1, L1, N, R2 and R3 are as defined herein. Further pro...
|
|
WO/2022/194399A1 |
The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharm...
|
|
WO/2022/194257A1 |
A compound of formula (II) and a preparation method therefor, and a method for preparing a camptothecin derivative and an antibody drug conjugate from the compound of formula (II). The preparation method for the compound of formula (II) ...
|
|
WO/2022/193038A1 |
Disclosed are a [18F]AlF labeled PSMA targeting molecular probe and a preparation method therefor, wherein the structural formula is as follows: 18F is used as a radioactive labeled nuclide, and a PSMA targeting molecular probe is labele...
|
|
WO/2022/190100A1 |
Disclosed herein are levodopa prodrug compounds and methods for their use. Further disclosed herein are liquid pharmaceutical formulations comprising a levodopa-tyrosine conjugate and a stabilizer, wherein the liquid pharmaceutical formu...
|
|
WO/2022/190486A1 |
The present invention provides, as a novel compound that can be utilized for efficient synthesis or the like of a polypeptide comprising various amino acids, a silane-containing condensed cyclic dipeptide compound represented by formula ...
|
|
WO/2022/188877A1 |
The present invention relates to the technical field of medicines. Disclosed are a synthetic peptide and an application thereof. The chemical formula of the synthetic peptide is (Gly)x-(beta-Ala-L-His)y-(Gly)z, (Gly)x-(beta-Ala-L-1-Methy...
|
|
WO/2022/188878A1 |
Provided is a multifunctional polypeptide, consisting of one or more of at least one Pro-Ala-Lys, Ala-Lys-Pro, Lys-Ala-Pro and a fragment thereof and a derived peptide, there being carnosine, anserine or ophidine at the C-terminus and/or...
|
|
WO/2022/186290A1 |
The present invention addresses the problem of providing a peptide having excellent dipeptidyl peptidase-IV (DPP-IV) inhibitory activity. An oligopeptide including any of the sequences described in (a) to (h) below. These oligopeptides m...
|
|
WO/2022/183993A1 |
Provided is a compound targeting a prostate specific membrane antigen (PSMA). The compound has a structure as represented by formula (I), wherein R1 is a compound targeting a prostate specific membrane antigen; L1 is -(X)n-(CH 2)m-(Y)q-,...
|
|
WO/2022/187491A1 |
Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
|
|
WO/2022/180410A1 |
The present invention provides a series of tripeptides according to the compound of formula (I) that inhibit the interaction of both HIF-1α and HIF-2α with HIf-1 β by binding to the PAS-B domain of the α subunit of HIF. The tripeptid...
|
|
WO/2022/178592A1 |
The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process...
|
|
WO/2022/174058A1 |
Disclosed are peptides having the structure according to formula (la) or (lb) or (II): wherein NH-Q-C(O) is a peptide chain optionally comprising an amino acid residue having a sidechain covalently bonded to Z2; Z1 is a moiety comprising...
|
